PRINCIPLE, the UK’s national priority clinical trial of COVID-19 treatments for recovery at home, has launched a new trial arm assessing favipiravir. Favipiravir is an antiviral drug licenced in Japan to treat influenza. People aged 50 - 64 with certain underlying health conditions or shortness of breath from COVID-19, or aged over 65, are eligible to join the favipiravir arm within the first 14 days of experiencing COVID-19 symptoms or receiving a positive test. People can join from anywhere in the UK, either online, over the phone or via a healthcare professional. If you think a patient may be interested in joining the study, visit the website.
PRINCIPLE – new trial
23 Apr 2021
Related updates
01 Jul 2022
NHSE Primary Care Bulletin 30 June
10 Mar 2022
Public Health advice for health professionals: people returning from Ukraine
08 Mar 2022
Get involved: NHS primary care staff wanted for photography and case studies
25 Feb 2022
NHSE: Covid-19 plans
23 Feb 2022
Social Prescribing Pathway Supporting Children and Young People Affected by Violence